Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) EBITDA (2017 - 2025)

VYNE Therapeutics (VYNE) has disclosed EBITDA for 9 consecutive years, with -$5.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA rose 38.72% year-over-year to -$5.8 million, compared with a TTM value of -$38.5 million through Jun 2025, down 35.12%, and an annual FY2025 reading of -$26.5 million, up 33.48% over the prior year.
  • EBITDA was -$5.8 million for Q2 2025 at VYNE Therapeutics, up from -$8.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$5.6 million in Q1 2023 and bottomed at -$12.1 million in Q3 2024.
  • Average EBITDA over 5 years is -$8.7 million, with a median of -$8.8 million recorded in 2021.
  • The sharpest move saw EBITDA skyrocketed 94.29% in 2021, then tumbled 95.33% in 2024.
  • Year by year, EBITDA stood at -$8.8 million in 2021, then increased by 9.73% to -$8.0 million in 2022, then grew by 22.82% to -$6.2 million in 2023, then tumbled by 95.33% to -$12.0 million in 2024, then skyrocketed by 52.17% to -$5.8 million in 2025.
  • Business Quant data shows EBITDA for VYNE at -$5.8 million in Q2 2025, -$8.6 million in Q1 2025, and -$12.0 million in Q4 2024.